GEN

First “Superbug Map” May Advance Phage Therapy for Acinetobacter baumannii

In an effort to illustrate that genomic surveillance can build the foundation for scaleable precision phage therapy, an international collaboration analyzed the genomes of over 15,000 cases of ...
Nasdaq

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet ...

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by ...
News Medical

Heart drug repurposed to kill hospital superbug Acinetobacter baumannii

A new study from Emory University addresses the growing global crisis of antibiotic-resistant infections. Many of these drug-resistant bacteria are spread through hospitals, and there are few ...
Nasdaq

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated ...

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems ...